Molecular Oncology
Volume 4, Issue 5 , Pages 443-450 , October 2010

Targeting leukemic stem cells by breaking their dormancy

Received 4 May 2010 ,Revised 1 June 2010 ,Accepted 1 June 2010.

References 

  1. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer. 2007;7:834–846
  2. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev. Drug Discov. 2007;6:975–990
  3. Cho RW, Clarke MF. Recent advances in cancer stem cells. Curr. Opin. Genet. Dev. 2008;18:48–53
  4. de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM, et al. Functional classification of interferon-stimulated genes identified using microarrays. J. Leukoc. Biol. 2001;69:912–920
  5. Dick JE. Stem cell concepts renew cancer research. Blood. 2008;112:4793–4807
  6. Drummond MW, Heaney N, Kaeda J, Nicolini FE, Clark RE, Wilson G, et al A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. Leukemia. 2009;23:1199–1201
  7. Eaves CJ. Cancer stem cells: here, there, everywhere?. Nature. 2008;456:581–582
  8. Ema H, Sudo K, Seita J, Matsubara A, Morita Y, Osawa M, et al. Quantification of self-renewal capacity in single hematopoietic stem cells from normal and Lnk-deficient mice. Dev. Cell. 2005;8:907–914
  9. Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature. 2009;458:904–908
  10. Foudi A, Hochedlinger K, Van Buren D, Schindler JW, Jaenisch R, Carey V, et al. Analysis of histone 2B-GFP retention reveals slowly cycling hematopoietic stem cells. Nat. Biotechnol. 2009;27:84–90
  11. Fuchs E. The tortoise and the hair: slow-cycling cells in the stem cell race. Cell. 2009;137:811–819
  12. Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood. 2007;110:2828–2837
  13. Goldman JM. Treatment strategies for CML. Best Pract. Res. Clin. Haematol. 2009;22:303–313
  14. Goldman JM, Green AR, Holyoake T, Jamieson C, Mesa R, Mughal T, et al. Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues. Leukemia. 2009;23:1708–1715
  15. Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR, et al Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell. 2002;109:625–637
  16. Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature. 2008;453:1072–1078
  17. Ito K, Bernardi R, Pandolfi PP. A novel signaling network as a critical rheostat for the biology and maintenance of the normal stem cell and the cancer-initiating cell. Curr. Opin. Genet. Dev. 2009;19:51–59
  18. Jorgensen HG, Copland M, Allan EK, Jiang X, Eaves A, Eaves C, et al. Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clin. Cancer Res. 2006;12:626–633
  19. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science. 2007;317:337
  20. Kiel MJ, Yilmaz OH, Iwashita T, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005;121:1109–1121
  21. Majeti R, Park CY, Weissman IL. Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Cell Stem Cell. 2007;1:635–645
  22. McDermott, S.P., Eppert, K., Lechman, E., Doedens, M., Dick, J.E., 2010. Comparison of human cord blood engraftment between immunocompromised mouse strains. Blood. Epub ahead of print.
  23. Morrison SJ, Wright DE, Weissman IL. Cyclophosphamide/granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization. Proc. Natl. Acad. Sci. U. S. A. 1997;94:1908–1913
  24. Nasr R, Guillemin MC, Ferhi O, Soilihi H, Peres L, Berthier C, et al Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat. Med. 2008;14:1333–1342
  25. Nasr R, Lallemand-Breitenbach V, Zhu J, Guillemin MC, de The H. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure. Clin. Cancer Res. 2009;15:6321–6326
  26. Osawa M, Hanada K, Hamada H, Nakauchi H. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science. 1996;273:242–245
  27. Passegue E, Rafii S, Herlyn M. Cancer stem cells are everywhere. Nat. Med. 2009;15:23
  28. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, et al G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat. Immunol. 2002;3:687–694
  29. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature. 2008;456:593–598
  30. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–111
  31. Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat. Med. 2006;12:1181–1184
  32. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, et al Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007;109:58–60
  33. Saito Y, Uchida N, Tanaka S, Suzuki N, Tomizawa-Murasawa M, Sone A, et al Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat. Biotechnol. 2010;28:275–280
  34. Sato T, Onai N, Yoshihara H, Arai F, Suda T, Ohteki T. Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. Nat. Med. 2009;15:696–700
  35. Shizuru JA, Negrin RS, Weissman IL. Hematopoietic stem and progenitor cells: clinical and preclinical regeneration of the hematolymphoid system. Annu. Rev. Med. 2005;56:509–538
  36. Trumpp A, Essers M, Wilson A. Awakening dormant haematopoietic stem cells. Nat. Rev. Immunol. 2010;10:201–209
  37. Trumpp A, Wiestler OD. Mechanisms of Disease: cancer stem cells – targeting the evil twin. Nat. Clin. Pract. Oncol. 2008;5:337–347
  38. van der Wath RC, Wilson A, Laurenti E, Trumpp A, Lio P. Estimating dormant and active hematopoietic stem cell kinetics through extensive modeling of bromodeoxyuridine label-retaining cell dynamics. PLoS One. 2009;4:e6972
  39. Venezia TA, Merchant AA, Ramos CA, Whitehouse NL, Young AS, Shaw CA, et al. Molecular signatures of proliferation and quiescence in hematopoietic stem cells. PLoS Biol. 2004;2:e301
  40. Wang JC, Dick JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 2005;15:494–501
  41. Wilson A, Laurenti E, Oser G, van der Wath RC, Blanco-Bose W, Jaworski M, et al Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell. 2008;135:1118–1129
  42. Wilson A, Laurenti E, Trumpp A. Balancing dormant and self-renewing hematopoietic stem cells. Curr. Opin. Genet. Dev. 2009;19:461–468
  43. Wilson A, Oser GM, Jaworski M, Blanco-Bose WE, Laurenti E, Adolphe C, et al. Dormant and self-renewing hematopoietic stem cells and their niches. Ann. N. Y. Acad. Sci. 2007;1106:64–75
  44. Xie T. Stem cell in the adult Drosophila hindgut: just a sleeping beauty. Cell Stem Cell. 2009;5:227–228
  45. Yamazaki S, Iwama A, Takayanagi S, Morita Y, Eto K, Ema H, et al. Cytokine signals modulated via lipid rafts mimic niche signals and induce hibernation in hematopoietic stem cells. EMBO J. 2006;25:3515–3523
  46. Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, et al Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science. 2010;328:240–243
  47. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 2009;8:806–823

PII: S1574-7891(10)00047-5

doi: 10.1016/j.molonc.2010.06.001

Molecular Oncology
Volume 4, Issue 5 , Pages 443-450 , October 2010

Article Tools

* Image Usage & Resolution